ESTRO 2024 - Abstract Book

S1742

Clinical - Lung

ESTRO 2024

Stokes WA, Bronsert MR, Meguid RA, Blum MG, Jones BL, Koshy M, et al. Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early Stage Non – Small-Cell Lung Cancer. Journal of Clinical Oncology 2018;36:642 – 51. https://doi.org/10.1200/JCO.2017.75.6536. Spencer KL, Kennedy MPT, Lummis KL, Ellames DAB, Snee M, Brunelli A, et al. Surgery or radiotherapy for stage I lung cancer? An intention to treat analysis. European Respiratory Journal 2019:1801568. https://doi.org/10.1183/13993003.01568-2018.

2538

Digital Poster

Clinical and dosimetric predictors of cardiotoxicity for locally advanced lung cancer

Eugènia Otero Pla 1 , Ana María Soto Cambres 1 , Pedro Gallego Franco 2 , Núria Jornet Sala 2 , Saba rabi 1 , Scarlet Marie Crespo Pérez 1 , Gemma Calvet Molinas 1 , Judit Sanz Beltrán 3 , Sergio Martínez Recio 3 , Sonia Bermejo Martínez 1 , Gemma Sancho Pardo 1 , Núria Farré Bernadó 1 1 Hospital de la Santa Creu i Sant Pau, Radiation Oncology, Barcelona, Spain. 2 Hospital de la Santa Creu i Sant Pau, Medical Physics, Barcelona, Spain. 3 Hospital de la Santa Creu i Sant Pau, Medical Oncology, Barcelona, Spain

Purpose/Objective:

To investigate the impact of cardiovascular risk factors (CVRF), antineoplastic treatment and dosimetric parameters in the overall survival (OS) and in the prevalence of cardiac events in locally advanced lung cancer patients treated with chemo-radiotherapy (Ch-RT). To evaluate the coronary artery calcium (CAC) on planning CT scan as a predictive parameter for the risk of cardiac events

Material/Methods:

Patients diagnosed with locally advanced lung cancer treated with Ch-RT in our institution between 2015 from 2019 were selected for analysis. We extracted clinical data and cardiac events from medical records and dosimetry parameters from the treatment planning system (EclipseTM Varian). A script was created within the ESAPI of Eclipse, to detect CAC in the structure contoured as heart. We performed our statistical analysis with SPSS software (Kaplan Meier and Cox regression analysis).

Results:

Our cohort included 135 patients, 71.1% male, median age 69 years (46-89). Most patients (93.3%) had smoking habit, 71.1% presented CVRF and 31.8% had prior cardiovascular disease (CVD). Treatment regimens were: concurrent Ch-RT (56.3%), sequential Ch-RT (31.9%) and radiotherapy alone (11.9%); followed with surgery (17%) and immunotherapy (10.4%). Patients were treated with 3DCRT or IMRT. The prescription dose to the PTV was ≥60Gy for 82.8% patients. 87.4% received platinum -based doublet for <3 cycles.